Probiotics and immunity: Provisional role for personalized diets and disease prevention

EPMA Journal

Volumn 6, Issue 1, 2015, Pages

  Bubnov, Rostyslav V ^a,b   Spivak, Mykola Ya ^a,c   Lazarenko, Liudmyla M ^a   Bomba, Alojz ^d,e   Boyko, Nadiya V ^a,d  

^a ZABOLOTNY INSTITUTE OF MICROBIOLOGY AND VIROLOGY   (Ukraine)

^b Clinical Hospital Pheophania of State Affairs Department   (Ukraine)

^c LCL Diaprof   (Ukraine)

^d Cassovia Life Sciences   (Slovakia)

^e P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

and personalized medicine; Bifidobacterium; Cancer; Dietary biomarkers; Fecal microbiota transplantation; Gut microbiota; Gut brain axis; Healthy diet; Immune disorders; Lactobacillus; Microbiome; Nutrition; Pattern recognition receptors; Predictive; Preventive

Indexed keywords

KEFIR; PROBIOTIC AGENT; SEROTONIN;

ALLERGY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APUD CELL; ASTHMA; ATOPY; CANCER PREVENTION; CANCER RISK; CHRONIC LIVER DISEASE; DIET; DRUG EFFECT; HUMAN; IMAGING; IMMUNITY; IMMUNOMODULATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; INSULIN RESISTANCE; INTESTINE FLORA; METABOLIC DISORDER; METABOLOME; MUCOSAL IMMUNITY; MUSCULOSKELETAL DISEASE; NANOBIOTECHNOLOGY; NEOPLASM; NEUROENDOCRINE SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PAIN; PERSONALIZED DIET; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEX DIFFERENCE; T LYMPHOCYTE;

EID: 84937909858     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/s13167-015-0036-0     Document Type: Review

References (115)

1. Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3:14.
2. Golubnitschaja O, Costigliola V, EPMA. EPMA summit 2014 under the auspices of the presidency of Italy in the EU: professional statements. EPMA J. 2015;6:4.
3. Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, et al. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015;6:9.
4. Mokrozub VV, Lazarenko LM, Sichel LM, Bubnov RV, Spivak MY. The role of beneficial bacteria wall elasticity in regulating innate immune response. EPMA J. 2015;6:13.
5. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol. 2011;12(1):5-9. doi: 10.1038/ni0111-5 .
6. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259-60.
7. Toh ZQ, Anzela A, Tang ML, Licciardi PV. Probiotic therapy as a novel approach for allergic disease. Front Pharmacol. 2012;3:171.
8. Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol. 2014;106(4):751-62.
9. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. Science. 2002;296(5567):490-4.
10. Isolauri E, Salminen S. Nutrition, Allergy, Mucosal Immunology, and Intestinal Microbiota (NAMI) Research Group Report. Probiotics: use in allergic disorders: a Nutrition, Allergy, Mucosal Immunology, and Intestinal Microbiota (NAMI) Research Group report. J Clin Gastroenterol. 2008;42 Suppl 2:S91-6.
11. Shinkai K, Mohrs M, Locksley RM. Helper T cells regulate type-2 innate immunity in vivo. Nature. 2002;420(6917):825-9.
12. Zeuthen LH, Fink LN, Frøkiaer H. Toll-like receptor 2 and nucleotide-binding oligomerization domain-2 play divergent roles in the recognition of gut-derived lactobacilli and bifidobacteria in dendritic cells. Immunology. 2008;124(4):489-502. doi: 10.1111/j.1365 .
13. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5(10):987-95.
14. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10(7):479-89.
15. Fukata M, Abreu MT. TLR4 signalling in the intestine in health and disease. Biochem Soc Trans. 2007;35:1473-8.
16. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol. 2011;9(4):279-90. doi: 10.1038/nrmicro2540 .
17. Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol. 2013;11:639-47.
18. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013;4:1829.
19. Starovoitova SA, Babenko LP, Timoshok NA, Shynkarenko LN, Lazarenko LN, Spivak NY. Cholesterol-lowering activity of lactic acid bacteria probiotic strains in vivo. Mikrobiol Z. 2012;74(3):78-85.
20. Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr. 2010;64:636-43.
21. Luoto R, Kalliomäki M, Laitinen K, Isolauri E. The impact of perinatal probiotic intervention on the development of overweight and obesity: follow-up study from birth to 10 years. Int J Obes (Lond). 2010;34(10):1531-7.
22. Cakir T, Patil KR, Onsan Z, Ulgen KO, Kirdar B, Nielsen J. Integration of metabolome data with metabolic networks reveals reporter reactions. Mol Syst Biol. 2006;2:50.
23. Ono T, Murakoshi M, Suzuki N, Iida N, Ohdera M, Iigo M, et al. Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. Br J Nutr. 2010;104(11):1688-95.
24. Savcheniuk OA, Virchenko OV, Falalyeyeva TM, Beregova TV, Babenko LP, Lazarenko LM, et al. The efficacy of probiotics for monosodium glutamate-induced obesity: dietology concerns and opportunities for prevention. EPMA J. 2014;5:2.
25. Garrote GL, Abraham AG, De Antoni GL. Chemical and microbiological characterization of kefir grains. J Dairy Res. 2001;68(4):639-52.
26. Chen YP, Hsiao PJ, Hong WS, Dai TY, Chen MJ. Lactobacillus kefiranofaciens M1 isolated from milk kefir grains ameliorates experimental colitis in vitro and in vivo. J Dairy Sci. 2012;95(1):63-74. doi: 10.3168/jds.2011-4696 .
27. Kinross JM, Darzi AW, Nicholson JK. Gut microbiome-host interactions in health and disease. Genome Med. 2011;3(3):14. doi: 10.1186/gm228 .
28. Cani PD, Van Hul M. Novel opportunities for next-generation probiotics targeting metabolic syndrome. Curr Opin Biotechnol. 2015;32:21-7. doi: 10.1016/j.copbio.2014.10.006 .
29. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA. 2013;110:9066-71.
30. Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet induced obese mice. Gut. 2014;63:727-35.
31. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res. 2011;108(9):1133-45. doi: 10.1161/CIRCRESAHA.110.226936 .
32. Hong WS, Chen YP, Dai TY, Huang IN, Chen MJ. Effect of heat-inactivated kefir-isolated Lactobacillus kefiranofaciens M1 on preventing an allergic airway response in mice. J Agric Food Chem. 2011;59(16):9022-31.
33. Saenz SA, Taylor BC, Artis D. Welcome to the neighborhood: epithelial cell derived cytokines license innate and adaptive immune responses at mucosal sites. Immunological Rev. 2008;226:172-90.
34. Wu CT, Chen PJ, Lee YT, Ko JL, Lue KH. Effects of immunomodulatory supplementation with Lactobacillus rhamnosus on airway inflammation in a mouse asthma model. J Microbiol Immunol Infect. 2014;S1684-1182:00168-6.
35. Yu J, Jang SO, Kim BJ, Song YH, Kwon JW, Kang MJ, et al. The effects of Lactobacillus rhamnosus on the prevention of asthma in a murine model. Allergy Asthma Immunol Res. 2010;2(3):199-205.
36. Lee YT, Lee SS, Sun HL, Lu KH, Ku MS, Sheu JN, et al. Effect of the fungal immunomodulatory protein FIP-fve on airway inflammation and cytokine production in mouse asthma model. Cytokine. 2013;61(1):237-44.
37. Belikoff BG, Vaickus LJ, Sitkovsky M, Remick DG. A2B adenosine receptor expression by myeloid cells is proinflammatory in murine allergic-airway inflammation. J Immunol. 2012;189(7):3707-13.
38. Schultz MJ, Haas LE. Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review. Crit Care. 2011;15(1):R18.
39. Ricciardolo FL, Sabatini F, Sorbello V, Benedetto S, Defilippi I, Petecchia L, et al. Expression of vascular remodelling markers in relation to bradykinin receptors in asthma and COPD. Thorax. 2013;68(9):803-11. doi: 10.1136/thoraxjnl-2012-202741 .
40. Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino A, et al. Flammer syndrome. EPMA J. 2014;5:11.
41. Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA J. 2014;5:21.
42. Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol. 2010;16(4):403-10.
43. Imani Fooladi AA, Mahmoodzadeh Hosseini H, Nourani MR, Khani S, Alavian SM. Probiotic as a novel treatment strategy against liver disease. Hepat Mon. 2013;13(2), e7521. doi: 10.5812/hepatmon.7521 .
44. Savcheniuk O, Kobyliak N, Kondro M, Virchenko O, Falalyeyeva T, Beregova TL. Short-term periodic consumption of multiprobiotic from childhood improves insulin sensitivity, prevents development of non-alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced obesity. BMC Complement Altern Med. 2014;14:247. doi: 10.1186/1472-6882-14-247 .
45. Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014;7:12-8.
46. Hirabara SM, Gorjão R, Vinolo MA, Rodrigues AC, Nachbar RT, Curi R. Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol. 2012;2012:379024.
47. Esteve E, Ricart W, Fernández-Real JM. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance? Curr Opin Clin Nutr Metab Care. 2011;14(5):483-90.
48. Gomes AC, Bueno AA, de Souza RG, Mota JF. Gut microbiota, probiotics and diabetes. Nutr J. 2014;13:60. doi: 10.1186/1475-2891-13-60 .
49. Bonifacio E, Ziegler AG, Klingensmith G, Schober E, Bingley PJ, Rottenkolber M, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the pre-point randomized clinical trial. JAMA. 2015;313(15):1541-9.
50. Skyler JS. Toward primary prevention of type 1 diabetes. JAMA. 2015;313(15):1520-1.
51. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett C, Knight R, Gordon JI. The human microbiome project: exploring the microbial part of ourselves in a changing world. Nature. 2007;449(7164):804-10. doi: 10.1038/nature06244 .
52. Bäckhed F. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: the normal gut microbiota in health and disease. Clin Exp Immunol. 2010;160(1):80-4.
53. Borre YE, Moloney RD, Clarke G, Dinan TG, Cryan JF. The impact of microbiota on brain and behavior: mechanisms & therapeutic potential. Adv Exp Med Biol. 2014;817:373-403.
54. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):701-12.
55. Moloney RD, Desbonnet L, Clarke G, Dinan TG, Cryan JF. The microbiome: stress, health and disease. Mamm Genome. 2014;25(1-2):49-74.
56. Reardon S. Gut-brain link grabs neuroscientists. Nature. 2014;515:175-7.
57. Sherman MP, Zaghouani H, Niklas V. Gut microbiota, the immune system, and diet influence the neonatal gut-brain axis. Pediatr Res. 2015;77(1-2):127-35. doi: 10.1038/pr.2014.161 .
58. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355-66.
59. Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol. 2010;161:19-27.
60. Li Z, Chalazonitis A, Huang YY, Mann JJ, Margolis KG, Yang QM, et al. Essential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric dopaminergic neurons. J Neurosci. 2011;31:8998-9009.
61. Crane JD, Palanivel R, Mottillo EP, Bujak AL, Wang H, Ford RJ, et al. Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat Med. 2015;21(2):166-72.
62. Vitetta L, Coulson S, Linnane AW, Butt H. The gastrointestinal microbiome and musculoskeletal diseases: a beneficial role for probiotics and prebiotics. Pathogens. 2013;2(4):606-26. doi: 10.3390/pathogens2040606 .
63. Fiorentino PM, Tallents RH, Miller JN, Brouxhon SM, O'Banion MK, Puzas JE, et al. Spinal interleukin-1beta in a mouse model of arthritis and joint pain. Arthritis Rheum. 2008;58(10):3100-9. doi: 10.1002/art.23866 .
64. Bubnov RV. Evidence-based pain management: is the concept of integrative medicine applicable? EPMA J. 2012;3(1):13.
65. Centeno C: Orthopedics 2.0-How regenerative medicine and interventional orthopedics will change everything-3rd Edition. Edited by Chris Centeno, Regenexx: 2014. [ http://www.regenexx.com/orthopedics2/ ].
66. Bubnov R, Yevseenko V, Semeniv I. Ultrasound guided injections of platelets rich plasma for muscle injury in professional athletes. Comparative study. Med Ultrason. 2013;15(2):101-5.
67. Vaahtovuo J, Munukka E. KorkeamakiM, Luukkainen R, Toivanen P. Fecal microbiota in early rheumatoid arthritis. J Rheumatol. 2008;35(8):1500-5.
68. Yeoh N, Burton JP, Suppiah P, Reid G, Stebbings S. The role of the microbiome in rheumatic diseases. Curr Rheumatol Rep. 2013;15(3):314. doi: 10.1007/s11926-012-0314-y .
69. Brusca SB, Abramson SB, Scher JU. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr Opin Rheumatol. 2014;26(1):101-7. doi: 10.1097/BOR.0000000000000008 .
70. Van den Broek MF, van Bruggen MC, Koopman JP, Hazenberg MP, van den Berg WB. Gut flora induces and maintains resistance against streptococcal cell wall-induced arthritis in F344 rats. Clin Exp Immunol. 1992;88(2):313-7.
71. Scotece M, Conde J, Gómez R, López V, Pino J, González A, et al. Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases. Mediat Inflamm. 2012;2012:1-14.
72. Berthelot J-M, Le Goff B. Rheumatoid arthritis and periodontal disease. Joint Bone Spine. 2010;77(6):537-41.
73. Demoruelle MK, Weisman MH, Simonian PL, Lynch DA, Sachs PB, Pedraza IF, et al. Brief Report: Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64(6):1756-61.
74. Kumar KS, Sastry N, Polaki Hu Mishra V. Colon cancer prevention through probiotics: an overview. J Cancer Sci Ther. 2015;7:3. doi: 10.4172/1948-5956.1000329 .
75. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342:967-70.
76. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971-6.
77. Hirayama K, Rafter J. The role of probiotic bacteria in cancer prevention. Microbes Infect. 2000;2(6):681-6.
78. Rafter JJ. Scientific basis of biomarkers and benefits of functional foods for reduction of disease risk: cancer. Br J Nutr. 2002;88 Suppl 2:S219-24.
79. Bomba A, Brandeburová A, Ričanyová J, Strojný L, Chmelarová A, Szabadosová V, et al. The role of probiotics and natural bioactive compounds in modulation of the common molecular pathways in pathogenesis of atherosclerosis and cancer. Biologia. 2012;67(1):1-13.
80. Yu Y, Champer J, Beynet D, Kim J, Friedman AJ. The role of the cutaneous microbiome in skin cancer: lessons learned from the gut. J Drugs Dermatol. 2015;14(5):461-5.
81. Shapira N. Women's higher health risks in the obesogenic environment: a gender nutrition approach to metabolic dimorphism with predictive, preventive, and personalised medicine. EPMA J. 2013;4(1):1.
82. Goncharenko VM, Beniuk VA, Kalenska OV, Demchenko OM, Spivak MY, Bubnov RV. Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age. EPMA J. 2013;4:24.
83. Mändar R, Punab M, Borovkova N, Lapp E, Kiiker R, Korrovits P, et al. Complementary seminovaginal microbiome in couples. Res Microbiol. 2015;166(5):440-7.
84. Ma B, Forney LJ, Ravel J. Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol. 2012;66:371-89. doi: 10.1146/annurev-micro-092611-150157 .
85. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-9.
86. Mattila E, Uusitalo-Seppälä R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142(3):490-6.
87. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48(8):693-702.
88. Di Bella S, Gouliouris T, Petrosillo N. Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. J Infect Chemother. 2015;21(4):230-7. doi: 10.1016/j.jiac.2015.01.011 .
89. Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis. 2015;15(1):191.
90. Rossen NG, Fuentes S, van der Spek MJ, Tijssen J, Hartman JH, Duflou A, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149(1):110-8. doi: 10.1053/j.gastro.2015.03.045 . 1.
91. Ianiro G, Bibbò S, Scaldaferri F, Gasbarrini A, Cammarota G. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore). 2014;93(19):e97.
92. Trovato GM. Behavior, nutrition and lifestyle in a comprehensive health and disease paradigm: skills and knowledge for a predictive, preventive and personalized medicine. EPMA J. 2012;3(1):8.
93. http://ec.europa.eu/index_en.htm . Accessed 22 May 2015.
94. http://www.healthydietforhealthylife.eu/ . Accessed 22 May 2015.
95. Jenab M, Slimani N, Bictash M, Ferrari P, Bingham SA. Biomarkers in nutritional epidemiology: applications, needs and new horizons. Hum Genet. 2009;125(5-6):507-25.
96. Hedrick VE, Dietrich AM, Estabrooks PA, Savla J, Serrano E, Davy BM. Dietary biomarkers: advances, limitations and future directions. Nutr J. 2012;11:109.
97. Holscher HD, Caporaso JG, Hooda S, Brulc JM, Fahey Jr GC, Swanson KS. Fiber supplementation influences phylogenetic structure and functional capacity of the human intestinal microbiome: follow-up of a randomized controlled trial. Am J Clin Nutr. 2015;101(1):55-64. doi: 10.3945/ajcn.114.092064
98. "UNESCO-culture-intangible heritage-lists & register-inscribed elements-Mediterranean diet". http://www.unesco.org/culture/ich/index.php?lg=en&pg=00011&RL=00884 . Accessed 22 May 2015.
99. Albuquerque TG, Costa HS, Sanches-Silva A, Santos M, Trichopoulou A, D'Antuono F, et al. Traditional foods from the Black Sea region as a potential source of minerals. J Sci Food Agric. 2013;93(14):3535-44. doi: 10.1002/jsfa.6164 .
100. http://ec.europa.eu/research/innovation-union/index_en.cfm . Accessed 22 May 2015.
101. Gibson GR, Roberfroid MB. Dietary modulation of the colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401-12.
102. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev. 2004;17(2):259-75. doi: 10.1079/NRR200479 .
103. Hijová E, Bomba A, Bertková I, Strojný L, Szabadosová V, Šoltésová A. Prebiotics and bioactive natural substances induce changes of composition and metabolic activities of the colonic microflora in cancerous rats. Acta Biochim Pol. 2012;59(2):271-4.
104. Haghshenas B, Abdullah N, Nami Y, Radiah D, Rosli R, Yari KA. Microencapsulation of probiotic bacteria Lactobacillus plantarum 15HN using alginate-psyllium-fenugreek polymeric blends. J Appl Microbiol. 2015;118(4):1048-57. doi: 10.1111/jam.12762 .
105. Spivak MY, Bubnov RV, Yemets IM, Lazarenko LM, Tymoshok NO, Ulberg ZR. Gold nanoparticles-the theranostic challenge for PPPM: nanocardiology application. EPMA J. 2013;4(1):18.
106. Spivak MY, Bubnov RV, Yemets IM, Lazarenko LM, Tymoshok NO, Ulberg ZR. Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology. EPMA J. 2013;4(1):20.
107. Zholobak NM, Sherbakov AB, Babenko LS, Bogorad-Kobelska OS, Bubnov RV, Spivak MYA, et al. The perspectives of biomedical application of the nanoceria. EPMA J. 2014;5 Suppl 1:A136.
108. Spivak NY, Shepel EA, Zholobak NM, Shcherbakov AB, Antonovitch GV, Yanchiy RI, et al. Ceria nanoparticles boost activity of aged murine oocytes. Nano Biomed Eng. 2012;4(4):188-94.
109. Kobyliak NM, Falalyeyeva TM, Kuryk OG, Beregova TV, Bodnar PM, Zholobak NM, et al. Antioxidative effects of cerium dioxide nanoparticles ameliorate age-related male infertility: optimistic results in rats and the review of clinical clues for integrative concept of men health and fertility. EPMA J. 2015;6:12.
110. Yefimenko OY, Savchenko YO, Falalyeyeva TM, Beregova TV, Zholobak NM, Spivak MY, et al. Nanocrystaline cerium dioxide efficacy for gastrointestinal motility. Potential for prokinetic treatment and prevention in elderly. EPMA J. 2015;6:6.
111. [ http://gunainternational.com/ ] Accessed 22 May 2015.
112. Metchnikoff E. Lactic acid as inhibiting intestinal putrefaction. The prolongation of life: optimistic studies. London: William Heinemann; 1907. p. 161-83.
113. Clifford A, Hoffman GS. Evidence for a vascular microbiome and its role in vessel health and disease. Curr Opin Rheumatol. 2015;27(4):397-405.
114. MacIntyre DA, Chandiramani M, Lee YS, Kindinger L, Smith A, Angelopoulos N, et al. The vaginal microbiome during pregnancy and the postpartum period in a European population. Sci Rep. 2015;5:8988. doi: 10.1038/srep08988 .
115. Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 2013;4:7.